Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects

Jill C. Chappell, Graeme Eisenhofer, Michael J. Owens, Harry Haber, D. Richard Lachno, Robert A. Dean, Mary Pat Knadler, Charles Nemeroff, Malcolm I. Mitchell, Michael J. Detke, Smriti Iyengar, Beth Pangallo, Evelyn D. Lobo

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Duloxetine selectively inhibits the serotonin (5-HT) and norepinephrine (NE) transporters (5-HTT and NET, respectively), as demonstrated in vitro and in preclinical studies; however, transporter inhibition has not been fully assessed in vivo at the approved dose of 60 mg/d. Here, the in vivo effects of dosing with duloxetine 60 mg once daily for 11 days in healthy subjects were assessed in 2 studies: (1) centrally (n = 11), by measuring concentrations of 5-hydroxyindoleacetic acid, 3,4-dihydroxyphenylglycol (DHPG), and NE in cerebrospinal fluid, and (2) versus escitalopram 20 mg/d (n = 32) in a 2-period crossover study by assessing the ΔDHPG/ΔNE ratio in plasma during orthostatic testing and by pharmacokinetic/pharmacodynamic modeling of reuptake inhibition using subjects' serum in cell lines expressing cloned human 5-HTT or NET. At steady state, duloxetine significantly reduced concentrations of DHPG and 5-hydroxyindoleacetic acid (P < 0.05), but not NE, in cerebrospinal fluid; DHPG was also decreased in plasma and urine. The ΔDHPG/ΔNE ratio in plasma decreased significantly more with duloxetine than escitalopram (65% and 21%, respectively; P < 0.0001). Ex vivo reuptake inhibition of 5-HTT was comparable (EC50 = 44.5 nM) for duloxetine and escitalopram, but duloxetine inhibited NET more potently (EC50 = 116 nM and 1044 nM, respectively). Maximal predicted reuptake inhibition for 5-HTT was 84% for duloxetine and 80% for escitalopram, and that for NET was 67% and 14%, respectively. In summary, duloxetine significantly affected 5-HT and NE turnover in the central nervous system and periphery; these effects presumably occurred via inhibition of reuptake by the 5-HTT and NET, as indicated by effects on functional reuptake inhibition ex vivo.

Original languageEnglish
Pages (from-to)9-16
Number of pages8
JournalJournal of Clinical Psychopharmacology
Volume34
Issue number1
DOIs
StatePublished - Feb 1 2014

Fingerprint

Norepinephrine Plasma Membrane Transport Proteins
Serotonin Plasma Membrane Transport Proteins
Healthy Volunteers
Citalopram
Norepinephrine
Serotonin
Hydroxyindoleacetic Acid
Cerebrospinal Fluid
Duloxetine Hydrochloride
Cross-Over Studies
Central Nervous System
Pharmacokinetics
Urine
Cell Line

Keywords

  • 5-HIAA
  • CSF
  • DHPG
  • Duloxetine
  • Norepinephrine
  • Serotonin

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Chappell, J. C., Eisenhofer, G., Owens, M. J., Haber, H., Lachno, D. R., Dean, R. A., ... Lobo, E. D. (2014). Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects. Journal of Clinical Psychopharmacology, 34(1), 9-16. https://doi.org/10.1097/JCP.0000000000000061

Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects. / Chappell, Jill C.; Eisenhofer, Graeme; Owens, Michael J.; Haber, Harry; Lachno, D. Richard; Dean, Robert A.; Knadler, Mary Pat; Nemeroff, Charles; Mitchell, Malcolm I.; Detke, Michael J.; Iyengar, Smriti; Pangallo, Beth; Lobo, Evelyn D.

In: Journal of Clinical Psychopharmacology, Vol. 34, No. 1, 01.02.2014, p. 9-16.

Research output: Contribution to journalArticle

Chappell, JC, Eisenhofer, G, Owens, MJ, Haber, H, Lachno, DR, Dean, RA, Knadler, MP, Nemeroff, C, Mitchell, MI, Detke, MJ, Iyengar, S, Pangallo, B & Lobo, ED 2014, 'Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects', Journal of Clinical Psychopharmacology, vol. 34, no. 1, pp. 9-16. https://doi.org/10.1097/JCP.0000000000000061
Chappell, Jill C. ; Eisenhofer, Graeme ; Owens, Michael J. ; Haber, Harry ; Lachno, D. Richard ; Dean, Robert A. ; Knadler, Mary Pat ; Nemeroff, Charles ; Mitchell, Malcolm I. ; Detke, Michael J. ; Iyengar, Smriti ; Pangallo, Beth ; Lobo, Evelyn D. / Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects. In: Journal of Clinical Psychopharmacology. 2014 ; Vol. 34, No. 1. pp. 9-16.
@article{cf3d856421a445f6818e768eedb3a2d0,
title = "Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects",
abstract = "Duloxetine selectively inhibits the serotonin (5-HT) and norepinephrine (NE) transporters (5-HTT and NET, respectively), as demonstrated in vitro and in preclinical studies; however, transporter inhibition has not been fully assessed in vivo at the approved dose of 60 mg/d. Here, the in vivo effects of dosing with duloxetine 60 mg once daily for 11 days in healthy subjects were assessed in 2 studies: (1) centrally (n = 11), by measuring concentrations of 5-hydroxyindoleacetic acid, 3,4-dihydroxyphenylglycol (DHPG), and NE in cerebrospinal fluid, and (2) versus escitalopram 20 mg/d (n = 32) in a 2-period crossover study by assessing the ΔDHPG/ΔNE ratio in plasma during orthostatic testing and by pharmacokinetic/pharmacodynamic modeling of reuptake inhibition using subjects' serum in cell lines expressing cloned human 5-HTT or NET. At steady state, duloxetine significantly reduced concentrations of DHPG and 5-hydroxyindoleacetic acid (P < 0.05), but not NE, in cerebrospinal fluid; DHPG was also decreased in plasma and urine. The ΔDHPG/ΔNE ratio in plasma decreased significantly more with duloxetine than escitalopram (65{\%} and 21{\%}, respectively; P < 0.0001). Ex vivo reuptake inhibition of 5-HTT was comparable (EC50 = 44.5 nM) for duloxetine and escitalopram, but duloxetine inhibited NET more potently (EC50 = 116 nM and 1044 nM, respectively). Maximal predicted reuptake inhibition for 5-HTT was 84{\%} for duloxetine and 80{\%} for escitalopram, and that for NET was 67{\%} and 14{\%}, respectively. In summary, duloxetine significantly affected 5-HT and NE turnover in the central nervous system and periphery; these effects presumably occurred via inhibition of reuptake by the 5-HTT and NET, as indicated by effects on functional reuptake inhibition ex vivo.",
keywords = "5-HIAA, CSF, DHPG, Duloxetine, Norepinephrine, Serotonin",
author = "Chappell, {Jill C.} and Graeme Eisenhofer and Owens, {Michael J.} and Harry Haber and Lachno, {D. Richard} and Dean, {Robert A.} and Knadler, {Mary Pat} and Charles Nemeroff and Mitchell, {Malcolm I.} and Detke, {Michael J.} and Smriti Iyengar and Beth Pangallo and Lobo, {Evelyn D.}",
year = "2014",
month = "2",
day = "1",
doi = "10.1097/JCP.0000000000000061",
language = "English",
volume = "34",
pages = "9--16",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects

AU - Chappell, Jill C.

AU - Eisenhofer, Graeme

AU - Owens, Michael J.

AU - Haber, Harry

AU - Lachno, D. Richard

AU - Dean, Robert A.

AU - Knadler, Mary Pat

AU - Nemeroff, Charles

AU - Mitchell, Malcolm I.

AU - Detke, Michael J.

AU - Iyengar, Smriti

AU - Pangallo, Beth

AU - Lobo, Evelyn D.

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Duloxetine selectively inhibits the serotonin (5-HT) and norepinephrine (NE) transporters (5-HTT and NET, respectively), as demonstrated in vitro and in preclinical studies; however, transporter inhibition has not been fully assessed in vivo at the approved dose of 60 mg/d. Here, the in vivo effects of dosing with duloxetine 60 mg once daily for 11 days in healthy subjects were assessed in 2 studies: (1) centrally (n = 11), by measuring concentrations of 5-hydroxyindoleacetic acid, 3,4-dihydroxyphenylglycol (DHPG), and NE in cerebrospinal fluid, and (2) versus escitalopram 20 mg/d (n = 32) in a 2-period crossover study by assessing the ΔDHPG/ΔNE ratio in plasma during orthostatic testing and by pharmacokinetic/pharmacodynamic modeling of reuptake inhibition using subjects' serum in cell lines expressing cloned human 5-HTT or NET. At steady state, duloxetine significantly reduced concentrations of DHPG and 5-hydroxyindoleacetic acid (P < 0.05), but not NE, in cerebrospinal fluid; DHPG was also decreased in plasma and urine. The ΔDHPG/ΔNE ratio in plasma decreased significantly more with duloxetine than escitalopram (65% and 21%, respectively; P < 0.0001). Ex vivo reuptake inhibition of 5-HTT was comparable (EC50 = 44.5 nM) for duloxetine and escitalopram, but duloxetine inhibited NET more potently (EC50 = 116 nM and 1044 nM, respectively). Maximal predicted reuptake inhibition for 5-HTT was 84% for duloxetine and 80% for escitalopram, and that for NET was 67% and 14%, respectively. In summary, duloxetine significantly affected 5-HT and NE turnover in the central nervous system and periphery; these effects presumably occurred via inhibition of reuptake by the 5-HTT and NET, as indicated by effects on functional reuptake inhibition ex vivo.

AB - Duloxetine selectively inhibits the serotonin (5-HT) and norepinephrine (NE) transporters (5-HTT and NET, respectively), as demonstrated in vitro and in preclinical studies; however, transporter inhibition has not been fully assessed in vivo at the approved dose of 60 mg/d. Here, the in vivo effects of dosing with duloxetine 60 mg once daily for 11 days in healthy subjects were assessed in 2 studies: (1) centrally (n = 11), by measuring concentrations of 5-hydroxyindoleacetic acid, 3,4-dihydroxyphenylglycol (DHPG), and NE in cerebrospinal fluid, and (2) versus escitalopram 20 mg/d (n = 32) in a 2-period crossover study by assessing the ΔDHPG/ΔNE ratio in plasma during orthostatic testing and by pharmacokinetic/pharmacodynamic modeling of reuptake inhibition using subjects' serum in cell lines expressing cloned human 5-HTT or NET. At steady state, duloxetine significantly reduced concentrations of DHPG and 5-hydroxyindoleacetic acid (P < 0.05), but not NE, in cerebrospinal fluid; DHPG was also decreased in plasma and urine. The ΔDHPG/ΔNE ratio in plasma decreased significantly more with duloxetine than escitalopram (65% and 21%, respectively; P < 0.0001). Ex vivo reuptake inhibition of 5-HTT was comparable (EC50 = 44.5 nM) for duloxetine and escitalopram, but duloxetine inhibited NET more potently (EC50 = 116 nM and 1044 nM, respectively). Maximal predicted reuptake inhibition for 5-HTT was 84% for duloxetine and 80% for escitalopram, and that for NET was 67% and 14%, respectively. In summary, duloxetine significantly affected 5-HT and NE turnover in the central nervous system and periphery; these effects presumably occurred via inhibition of reuptake by the 5-HTT and NET, as indicated by effects on functional reuptake inhibition ex vivo.

KW - 5-HIAA

KW - CSF

KW - DHPG

KW - Duloxetine

KW - Norepinephrine

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=84891738871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891738871&partnerID=8YFLogxK

U2 - 10.1097/JCP.0000000000000061

DO - 10.1097/JCP.0000000000000061

M3 - Article

C2 - 24346757

AN - SCOPUS:84891738871

VL - 34

SP - 9

EP - 16

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 1

ER -